Cardiogen vs Survodutide
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
CardiogenGLP-1 / Weight Loss Agonists
Survodutide- Summary
- Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Half-Life
- Short (minutes); gene-regulatory effects persist longer
- ~7 days
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Frequency
- Daily for 10–30 days
- Once weekly
- Key Benefits
- Cardioprotective effects on myocardial tissue
- Normalization of cardiomyocyte protein synthesis
- May improve cardiac rhythm and conduction
- Support for recovery from ischemic cardiac events
- Anti-aging effects on heart tissue
- Potential reduction in cardiac fibrosis
- Often combined with Epithalon for comprehensive cardiovascular longevity support
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Side Effects
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse cardiovascular events reported at standard doses
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Stacks With
- —
- —